Cargando…

Real-World Efficiency of Pharmacogenetic Screening for Carbamazepine-Induced Severe Cutaneous Adverse Reactions

OBJECTIVES: We evaluated the cost and efficiency of routine HLA-B*15∶02 screening to prevent carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (CBZ-SJS/TEN) in Hong Kong. METHODS: Data were extracted from patients who commenced CBZ as the first-ever AED treatment or teste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhibin, Liew, Danny, Kwan, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013087/ https://www.ncbi.nlm.nih.gov/pubmed/24806465 http://dx.doi.org/10.1371/journal.pone.0096990

Ejemplares similares

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
por: Chang, Chih-Jung, et al.
Publicado: (2020)

HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese
por: Nguyen, Dinh Van, et al.
Publicado: (2015)

The pharmacogenomics of carbamazepine-induced cutaneous adverse drug reaction in the South of Vietnam
por: Nguyen, Ai-Hoc, et al.
Publicado: (2023)

Severe Cutaneous Adverse Reaction Caused by Carbamazepine and Levofloxacin After Varicella Zoster Virus Infection
por: Wang, Meifang, et al.
Publicado: (2023)

Carbamazepine induced severe cutaneous vasculitis
por: Gutte, Rameshwar M., et al.
Publicado: (2013)

Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis
por: Biswas, Mohitosh, et al.
Publicado: (2022)

Pharmacogenetics to Avoid Adverse Drug Reactions
por: López-Fernández, Luis A.
Publicado: (2022)

Pharmacogenetics for severe adverse drug reactions induced by molecular‐targeted therapy
por: Udagawa, Chihiro, et al.
Publicado: (2020)

Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care
por: Sung, Cynthia, et al.
Publicado: (2020)

Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters
por: Iannaccone, Teresa, et al.
Publicado: (2021)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Treatments for Severe Cutaneous Adverse Reactions
por: Cho, Yung-Tsu, et al.
Publicado: (2017)

Genetics of Severe Cutaneous Adverse Reactions
por: Yang, Shang-Chen, et al.
Publicado: (2021)

Multi-Indication Carbamazepine and the Risk of Severe Cutaneous Adverse Drug Reactions in Korean Elderly Patients: A Korean Health Insurance Data-Based Study
por: Kim, Ji Young, et al.
Publicado: (2013)

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
por: García-González, Xandra, et al.
Publicado: (2021)

Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients
por: Sukasem, Chonlaphat, et al.
Publicado: (2018)

Genetic markers of severe cutaneous adverse reactions
por: Jung, Jae-Woo, et al.
Publicado: (2018)

The assessment of severe cutaneous adverse drug reactions
por: Copaescu, Ana M, et al.
Publicado: (2022)

Chemokines in Severe Cutaneous Adverse Reactions (SCARs)
por: Miyagawa, Fumi, et al.
Publicado: (2021)

Pharmacogenetics of CYP3A5 on Carbamazepine pharmacokinetics in epileptic patients developing toxicity
por: Al-Gahtany, Mubarak, et al.
Publicado: (2014)

Implementation of HLA-B*15:02 Genotyping as Standard-of-Care for Reducing Carbamazepine/Oxcarbazepine Induced Cutaneous Adverse Drug Reactions in Thailand
por: Tiwattanon, Kanyawan, et al.
Publicado: (2022)

Analysis of Adverse Drug Reactions with Carbamazepine and Oxcarbazepine at a Tertiary Care Hospital
por: Lee, Jung Eun, et al.
Publicado: (2020)

Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics
por: Piatkov, Irina, et al.
Publicado: (2012)

Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02
por: Simper, Gwendolin S., et al.
Publicado: (2018)

Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions
por: Orime, Mari
Publicado: (2017)

Recent Advances in Severe Cutaneous Adverse Drug Reaction
por: Das, Sudip, et al.
Publicado: (2018)

Real‐world evidence of population differences in allopurinol‐related severe cutaneous adverse reactions in East Asians: A population‐based cohort study
por: Sato, Tsugumichi, et al.
Publicado: (2021)

Pharmacogenetic testing in schizophrenia in real clinical practice: before or after antipsychotic -induced adverse drug reactions development?
por: Abdyrakhmanova, A., et al.
Publicado: (2022)

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
por: Cavallari, LH, et al.
Publicado: (2017)

Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine
por: Micaglio, Emanuele, et al.
Publicado: (2021)

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies
por: Wu, Ran, et al.
Publicado: (2016)

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
por: Fohner, Alison E., et al.
Publicado: (2020)

Multiple drug hypersensitivity associated with severe cutaneous adverse reaction
por: Lin Choo, Karen Jui, et al.
Publicado: (2014)

Analysis of B cell subsets in severe cutaneous adverse reaction
por: Azukizawa, Hiroaki, et al.
Publicado: (2014)

Cytotoxic Proteins and Therapeutic Targets in Severe Cutaneous Adverse Reactions
por: Su, Shih-Chi, et al.
Publicado: (2014)

Severe Cutaneous Adverse Drug Reactions: A Clinicoepidemiological Study
por: Sasidharanpillai, Sarita, et al.
Publicado: (2015)

Severe Cutaneous Adverse Reaction (SCAR): Clinical Pharmacologists’ Viewpoint
por: Shafiq, Nusrat, et al.
Publicado: (2022)

Severe Cutaneous Adverse Reactions Caused by Anti-Tubercular Drugs
por: Kim, Sang-Heon
Publicado: (2021)

ADVERSE CUTANEOUS DRUG REACTION
por: Nayak, Surajit, et al.
Publicado: (2008)

Cutaneous Adverse Reactions of Amiodarone
por: Jaworski, Krzysztof, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9i7aaombhm3v53jhlah72t33tt